JP6454346B2 - 芳香族複素環式化合物及び医薬におけるその応用 - Google Patents

芳香族複素環式化合物及び医薬におけるその応用 Download PDF

Info

Publication number
JP6454346B2
JP6454346B2 JP2016539025A JP2016539025A JP6454346B2 JP 6454346 B2 JP6454346 B2 JP 6454346B2 JP 2016539025 A JP2016539025 A JP 2016539025A JP 2016539025 A JP2016539025 A JP 2016539025A JP 6454346 B2 JP6454346 B2 JP 6454346B2
Authority
JP
Japan
Prior art keywords
mmol
compound
sulfonyl
methoxy
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016539025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540786A5 (enExample
JP2016540786A (ja
Inventor
チャン、インジュン
ジン、チャンフェイ
チョン、ウェンヘ
チャン、ジー
ガオ、リー
チェン、カンツィー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2016540786A publication Critical patent/JP2016540786A/ja
Publication of JP2016540786A5 publication Critical patent/JP2016540786A5/ja
Application granted granted Critical
Publication of JP6454346B2 publication Critical patent/JP6454346B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
JP2016539025A 2013-12-20 2014-12-19 芳香族複素環式化合物及び医薬におけるその応用 Active JP6454346B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310712676.9 2013-12-20
CN201310712676 2013-12-20
PCT/CN2014/094428 WO2015090233A1 (en) 2013-12-20 2014-12-19 Aromatic heterocyclic compounds and their application in pharmaceuticals

Publications (3)

Publication Number Publication Date
JP2016540786A JP2016540786A (ja) 2016-12-28
JP2016540786A5 JP2016540786A5 (enExample) 2018-01-18
JP6454346B2 true JP6454346B2 (ja) 2019-01-16

Family

ID=53402128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016539025A Active JP6454346B2 (ja) 2013-12-20 2014-12-19 芳香族複素環式化合物及び医薬におけるその応用

Country Status (5)

Country Link
US (1) US9663498B2 (enExample)
EP (1) EP3083588B1 (enExample)
JP (1) JP6454346B2 (enExample)
CN (1) CN104725295B (enExample)
WO (1) WO2015090233A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3703398B1 (en) 2013-11-22 2022-09-28 Huawei Device Co., Ltd. Method and apparatus for selecting information pushed-to terminal method and apparatus for selecting information pushed-to terminal
CA2953004C (en) * 2014-07-08 2023-02-21 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
CN106957254B (zh) * 2017-02-09 2019-11-15 郑州大学 一种3-烷氧基烷基吲哚衍生物及其制备方法和应用
CN109232362B (zh) * 2017-07-10 2022-12-27 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
WO2020117075A1 (en) * 2018-12-06 2020-06-11 Jagiellonian University Arylsulfonamides of 2-arylpyrrole-3-carboxamides for the treatment of cns disorders
CN116096371A (zh) * 2020-09-29 2023-05-09 广东东阳光药业有限公司 含有饱和含氧杂环基的嘧啶二酮类化合物及其用途

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE296811T1 (de) 1997-07-11 2005-06-15 Smithkline Beecham Plc Sulfonamid-derivate als 5-ht6 receptor antagonisten und verfahren zu ihrer herstellung
ATE236136T1 (de) 1998-01-16 2003-04-15 Hoffmann La Roche Benzosulfonderivate
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
US6133287A (en) 1998-03-24 2000-10-17 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-HT6 affinity
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
DE69937372T2 (de) 1999-04-21 2008-06-26 Nps Allelix Corp., Mississauga Piperidin-indol derivate mit 5-ht6 affinität
ATE268330T1 (de) 1999-08-12 2004-06-15 Nps Allelix Corp Azaidole mit serotonin rezeptor affinität
WO2001032660A1 (en) 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
WO2002032863A1 (en) 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
CN1222511C (zh) 2000-11-02 2005-10-12 惠氏公司 作为5－羟色胺－6配体的1－芳基－或1－烷基磺酰基－杂环基吲哚
WO2002041889A2 (en) 2000-11-24 2002-05-30 Smithkline Beecham P.L.C. Indolsulfonyl compounds useful in the treatment of cns disorders
DK1355904T3 (da) 2000-12-22 2007-10-15 Wyeth Corp Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
HUP0400682A2 (hu) 2000-12-22 2004-06-28 Wyeth 5-Hidroxitriptamin-6-ligandumként használható heterociklilalkilindol- és -azaindol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
BR0207302A (pt) 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
JP2004526781A (ja) 2001-04-20 2004-09-02 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロシクリルアルコキシ−、−アルキルチオ−および−アルキルアミノベンザゾール誘導体
PL367297A1 (en) 2001-04-20 2005-02-21 Wyeth Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
AU2002310747B2 (en) 2001-06-07 2007-10-11 F. Hoffmann-La Roche Ag New indole derivatives with 5-HT6 receptor affinity
BR0210291A (pt) 2001-06-11 2004-07-13 Biovitrum Ab Compostos de sulfonamida substituìdos, processo para sua preparação e seu uso como medicamento para o tratamento de distúrbios do sistema nervoso central, obesidade e diabetes do tipo ii
JP2005501019A (ja) 2001-06-15 2005-01-13 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６レセプター親和性を有する４−ピペラジニルインドール誘導体
PL373397A1 (en) 2001-08-10 2005-08-22 F.Hoffmann-La Roche Ag Arylsulfonyl derivatives with 5-ht6 receptor affinity
ATE335477T1 (de) 2001-12-20 2006-09-15 Wyeth Corp Indolylalkylamin-derivate als 5-hydroxytryptamin- 6 liganden
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
GB0202679D0 (en) 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
US6855709B2 (en) 2002-02-22 2005-02-15 Pharmacia & Upjohn Company Pyridyl sulfone derivatives
AU2003226724A1 (en) 2002-03-27 2003-10-08 Glaxo Group Limited Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
US6906095B2 (en) 2002-05-10 2005-06-14 Wyeth Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands
EP1513809A1 (en) 2002-06-05 2005-03-16 F. Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
BR0311952A (pt) 2002-06-20 2005-04-19 Biovitrum Ab Novos compostos úteis para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc
ATE362469T1 (de) 2002-09-17 2007-06-15 Hoffmann La Roche 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
JP4267573B2 (ja) 2002-09-17 2009-05-27 エフ．ホフマン−ラ ロシュ アーゲー ２，４−置換インドールおよびそれらの５−ｈｔ６モジュレーターとしての使用
ES2274285T3 (es) 2002-10-18 2007-05-16 F. Hoffmann-La Roche Ag 4-piperanzinilbencenosulfonilindoles con afinidad al receptor 5-ht6.
SI1567492T1 (sl) 2002-11-28 2013-07-31 Suven Life Sciences Limited N-arilsulfonil-3-aminoalkoksiindoli
CA2509982C (en) 2002-11-28 2011-11-08 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
SE0302760D0 (sv) 2003-10-20 2003-10-20 Biovitrum Ab New compounds
WO2005066157A1 (en) 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
PE20060303A1 (es) 2004-06-23 2006-05-19 Wyeth Corp Metabolitos de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
EP1632491A1 (en) 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
KR101016972B1 (ko) 2005-08-12 2011-02-25 수벤 라이프 사이언시스 리미티드 기능성 5-ｈｔ6 리간드인 아미노아릴 설폰아미드 유도체
WO2007020653A1 (en) 2005-08-12 2007-02-22 Suven Life Sciences Limited Thioether derivatives as functional 5-ht6 ligands
WO2007098418A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
WO2007138611A1 (en) 2006-05-30 2007-12-06 Suven Life Sciences Limited 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands
ES2398299T3 (es) 2006-07-03 2013-03-15 Proximagen Ltd. Indoles como moduladores de 5-HT6
EP2081890B1 (en) 2006-11-09 2011-01-12 F. Hoffmann-La Roche AG Arylsulfonyl pyrrolidines as 5-ht6 inhibitors
MX2009006077A (es) 2007-01-08 2009-06-17 Suven Life Sciences Ltd Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.
CA2672190C (en) 2007-01-08 2013-02-05 Suven Life Sciences Limited 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands
EP1947085A1 (en) 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
AU2008212887A1 (en) 2007-02-06 2008-08-14 Novartis Ag 1-benzenesulfonyl-1H-indole derivatives as inhibitors of CCR9 activity
US20080200471A1 (en) 2007-02-16 2008-08-21 Memory Pharmaceuticals Corporation 6' substituted compounds having 5-ht6 receptor affinity
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
RU2009139074A (ru) 2007-03-23 2011-04-27 Эбботт Гмбх Унд Ко.Кг (De) Азетидиновые соединения, подходящие для лечения расстройств, чувствительных к модуляции сеотонинового 5-нт6-рецептора
BRPI0809873A2 (pt) 2007-05-03 2018-11-13 Suven Life Sciences Ltd "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
US20080318941A1 (en) 2007-05-24 2008-12-25 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-ht6 receptor affinity
US20090069337A1 (en) 2007-08-15 2009-03-12 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-ht6 receptor affinity
WO2009034581A1 (en) 2007-09-11 2009-03-19 Suven Life Sciences Limited Substituted indolyl compounds and their use as 5-ht6 ligands
AU2008315309B2 (en) 2007-10-26 2011-06-09 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-HT6 ligands
US20100016297A1 (en) 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100056491A1 (en) 2008-08-29 2010-03-04 Memory Pharmaceuticals Corporation 4'-amino cyclic compounds having 5-ht6 receptor affinity
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
EP2424844A1 (en) 2009-04-30 2012-03-07 Abbott GmbH & Co. KG Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
CN102459197B (zh) 2009-04-30 2015-08-19 Abbvie公司 适用于治疗响应血清素5-ht6受体的调节的病症的n-苯基-(哌嗪基或高哌嗪基)-苯磺酰胺或苯磺酰基-苯基-(哌嗪或高哌嗪)化合物
JP2012525356A (ja) 2009-04-30 2012-10-22 アボット ゲーエムベーハー ウント カンパニー カーゲー セロトニン５−ｈｔ６受容体の調節に応答する障害を治療するのに適したベンゼンスルホンアニリド化合物
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8119683B2 (en) 2009-08-10 2012-02-21 Taipei Medical University Aryl substituted sulfonamide compounds and their use as anticancer agents
US8153680B2 (en) 2009-08-25 2012-04-10 The Ohio State University Research Foundation Alkyl indole-3-carbinol-derived antitumor agents
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012064744A2 (en) 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
WO2012170561A1 (en) 2011-06-06 2012-12-13 The Scripps Research Institute (T.S.R.I.) N-benzylindole modulators of pparg
CN104276993B (zh) 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
CN104557726B (zh) 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用

Also Published As

Publication number Publication date
US9663498B2 (en) 2017-05-30
CN104725295B (zh) 2019-05-24
CN104725295A (zh) 2015-06-24
WO2015090233A1 (en) 2015-06-25
EP3083588A1 (en) 2016-10-26
US20160251339A1 (en) 2016-09-01
JP2016540786A (ja) 2016-12-28
EP3083588A4 (en) 2017-12-27
EP3083588B1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
USRE50594E1 (en) Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
JP6318156B2 (ja) キナーゼをモジュレートするための化合物および方法、ならびにその指標
RU2680100C2 (ru) Гетероциклические соединения и их применения
CN107001385B (zh) 作为mdm2-p53抑制剂的螺-[3h-吲哚-3，2’-吡咯烷]-2(1h)-酮化合物及其衍生物
JP6649540B2 (ja) 置換されたヘテロアリール化合物および使用方法
JP6454346B2 (ja) 芳香族複素環式化合物及び医薬におけるその応用
EP2459558A2 (en) Compounds and compositions as syk kinase inhibitors
JP6515175B2 (ja) 芳香族ヘテロ環誘導体及びその医薬的適用
JP2018527362A (ja) 置換されたヘテロアリール化合物および使用方法
CN104557726A (zh) 芳杂环类衍生物及其在药物上的应用
WO2015158313A1 (en) Sulfonamide derivatives and pharmaceutical applications thereof
CN109232362B (zh) 芳杂环类衍生物及其在药物上的应用
CN116940571A (zh) 苯并异噁唑衍生物及其用途
CN106045967A (zh) 取代杂环化合物及其在药物上的应用
CN105367473B (zh) 吲哚啉类衍生物及其在药物上的应用
CN104529866A (zh) 吲哚类衍生物及其在药物上的应用
CN105367474A (zh) 吲哚啉类衍生物及其在药物上的应用
CN104496987A (zh) 取代杂环类化合物及其在药物上的应用
HK1232222B (en) Aromatic heterocyclic derivatives and pharmaceutical applications thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181214

R150 Certificate of patent or registration of utility model

Ref document number: 6454346

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250